Skip to Main Content

Improve the outlook

We believe chordoma is a solvable problem

We've put a plan in place to make chordoma a manageable disease. With the help of everyone affected, we could get there in time to help people facing chordoma today.

Our search for better treatments

Transformative new options are coming sooner than you think

Together, we’ve already changed much of what it means to face chordoma.

Yet the pressing need remains for better treatments. In the years ahead, our sights are set on treatments that can prevent recurrence, eliminate tumors rather than just slow their growth, and preserve patients’ quality of life. And thankfully, snowballing advances provide ever more tangible reasons to believe this is not only possible but probable.

Progress to date

When the Chordoma Foundation was founded in 2007, there was virtually no chordoma research being done and no infrastructure to enable it. Today, thanks to the extraordinary commitment of everyone affected by this disease, we've assembled a vibrant research community, created the scientific resources to make meaningful research happen, and seen therapies reach clinical trials. Our key achievements so far include:

Dozens of chordoma models developed

25+ disease targets revealed

250+ tumor samples collected

6,000 existing drugs screened

90+ drugs and combos tested preclinically

Helped 11 drugs reach clinical trials

Our next big leap

Chordoma Foundation Labs

In early 2022, we took the next step in accelerating new chordoma treatments by establishing our own laboratory. It's the first lab 100% dedicated to chordoma research, and our most powerful tool yet for progress.

Chordoma Foundation Labs is making it easier and more efficient to test new treatment ideas from anywhere in the world, and to significantly shorten the time from new biological insights to clinical trials.

Learn about our lab

Current strategies

For the first time, there's a credible path to far better treatments for chordoma patients — treatments that don’t just slow the disease down, but that have a real chance of enabling patients to get on with our lives. To achieve this ambitious goal at a pace that matches our shared sense of urgency, we're advancing a comprehensive research roadmap through multiple complementary initiatives that span every stage of treatment development.

Our investments to date, coupled with the new capabilities and speed afforded to us by Chordoma Foundation Labs, are leading to a rapid expansion of our clinical trials pipeline: This year and next, more well-justified therapeutic concepts will be ready to move from the lab into clinical trials than over the past five years combined.

Target discovery

All future treatments for chordoma patients will depend on a deep understanding of the biology of our disease: what drives it and what its weaknesses are.

Drug repurposing

Repurposing and repositioning existing drugs that may also work against chordoma allows us to bring new treatments to patients faster than developing new drugs from scratch.


Extraordinary advances are being made in the development of therapies that harness the immune system to fight cancer; our goal is to ensure that chordoma patients benefit from these powerful new approaches, too.

Brachyury drugs

A large body of research points to a protein called brachyury as the key driver of chordoma and its most critical vulnerability. We're bringing every plausible technology to bear to create brachyury-targeting drugs.

Ensuring children benefit from our advances

Pediatric chordoma

Pediatric chordoma may differ in important ways compared to the disease in adults, so we’re working to better understand its potentially unique biology and determine the best treatment approaches for children.

To that end, we’re collecting precious pediatric chordoma tumor samples, testing drugs against pediatric chordoma models, and looking for new vulnerabilities to target.

Learn more


View a list of research publications that have resulted from the Chordoma Foundation's work, resources, and support.

With adequate investment, new treatments are around the corner.

Tremendous ongoing support from everyone in our community makes us more optimistic than ever that we'll witness a completely new chordoma treatment landscape in our lifetimes. Thank you for giving patients and families real reasons for hope.


Gifts of every size will accelerate our therapeutic pipeline.

Give now


Rally your personal network to help us advance new chordoma treatments.

Start a fundraiser


To discuss other ways to drive progress against chordoma, reach out to our development team.

Get in touch

Latest research updates

Read all


Phase 2 afatinib results and other chordoma advances emerge from ASCO

The trial results demonstrate that a subset of chordoma patients benefit from afatinib for a sustained period, and create an urgent need to identify biomarkers that can predict a response to EGFR inhibitors.

Learn more


Promising results emerge from clinical trial testing ERAS-601 with or without cetuximab

The search for better treatments for advanced chordoma just took another step forward.

Learn more


New genetic findings emerge from chordoma Natural History Study

This paper represents the first notable findings to emerge from the chordoma cohort of the National Cancer Institute's Natural History Study of Rare Solid Tumors.

Learn more

Taking action

Navigating a rare cancer diagnosis: Insights from new book, “Fatal to Fearless”

Kathy Giusti's book is a roadmap for navigating a cancer diagnosis and its aftermath. It's also a testament to the power of learning, support, and action — a framework that many people in the chordoma community also embrace and exemplify.

Learn more

Sign up for our newsletter

To learn about exciting recent research results, newly launched projects, and how you can help drive progress, subscribe to our newsletter.